ABSTRACT Previous studies from this laboratory demonstrated that secondary hyperparathyroidism in dogs with chronic renal disease may ocecur, at least in part, as a consequience of the need for progressive adaptation in renal plhosphorus (P) excretion that occulrs as glomenilar filtration rate falls. However, the stuLdies were of relatively short dturation. Moreover, no information emerged regarding a potential role of calcitum malabsorption in the pathogenesis of secondary hyperparathyroidism. The short duration of the protocol did not lend itself to the stuidy of the effect of P control or the administration of vitamin D in the pathogenesis of renal osteodystrophy. In the present stuldies, 14 dogs with experimental chronic renal disease were studied serially for a period of 2 yr. Each animal was studied first with two normal kidneys on an intake of P of 1,200 mg/day. Then, renal insufficiency was produced by 5/6 nephrectomy. The dogs then were divided into three grouips. In group I, 1,200 mg/day P intake was administered for the full 2 yr. In group II, P intake was reduiced from the initial 1,200 mg/day, in proportion to the measured fall in glomerular filtration rate, in an effort to obviate the renal adaptation in P excretion. In grouip ILL, "proportional reduiction" of P intake also was employed; buit in addition, 20 ,ug of 25(OH)D3 were administered orally three times a week.
INTRODUCTION
The homeostatic mechanisms governing calcium and phosphorus metabolism are severely challenged by the loss of renal function. The adaptations required for the maintenance of external balance and the internal milieui occtcr predominantly, though not excllusively, throuigh alterations in two interrelated hormonal sys-phosphorus absorption does not occur. The adaptations required for the maintenance of phosphorus balance appear early in the course of the disease, whereas calcium malabsorption may be a relatively late phenomenon (4) . Evidence obtained during the past several years has served to implicate the requirement for an adaptive increase in fractional phosphate excretion, which accompanies the fall in glomerular filtration rate (GFR)l in chronic renal disease, as an important factor in the pathogenesis of secondary hyperparathyroidism (5, 6) . It was reasoned that if, during the evolution of chronic renal disease, the load of phosphorus to be excreted by the kidneys could be decreased in proportion to the fall in GFR, the requirement for an adaptive increase in the fractional phosphorus excretion could be negated and hyperparathyroidism could be minimized or prevented. When "proportional reduction" of phosphorus intake was employed in dogs in which renal mass and GFR were reduced in sequential steps, secondary hyperparathyroidism was in fact prevented (6, 7) . These observations were made over a relatively short period of time and the study designed did not allow for either the evaluation of the possible importance of calcium absorption or the effect of proportional reduction of phosphorus intake on renal osteodystrophy.
It is known that calcium malabsorption occurs in chronic renal failure, secondary to alterations in the metabolism of vitamin D (4, (8) (9) (10) (11) (12) . Vitamin D is first metabolized by the liver into 25(OH)D3 (13) (14) and then by the kidney into 1,25(OH)2D3 and other highly polar metabolites (15) (16) (17) (18) . Patients with chronic renal disease have low levels of 1,25(OH)2D3 secondary to the failure of the kidney to hydroxylate 25(OH)D3 in the carbon-i position (19) . A number of studies (10, (20) (21) (22) have demonstrated that calcium absorption may be normalized by the administration of 25(OH)2D3 and 1,25(OH)2D3, the latter being more potent. 1,25(OH)2D3 alone or synergistically with parathyroid hormone (PTH) stimulates osteoclastic activity and bone resorption. 25(OH)D3, although less potent than 1,25(OH)2D3, also has this capacity (23) , furthermore 25(OH)D3 or a metabolic derivative is important in the "maturation" of collagen and mineral (24) .
In this study, we have attempted to normalize the external balance of phosphorus and calcium by restricting phosphorus intake (in direct proportion to the decrease in GFR) and by normalizing calcium absorption by the administration of 25(OH)D3 in animals with moderately severe renal disease (20% of normal) over a long period of time (2 yr) in order ' Abbreviations used in this paper: CRD, chronic renal disease; GFR, glomerular filtration rate; P, phosphorus; PTH, parathyroid hormone.
to evaluate their effects on the development of secondary hyperparathyroidism and renal osteodystrophy.
METHODS
14 female mongrel dogs weighing 15-20 kg were tube fed 400 g of a fibrin-base low phosphorus (P) diet (Nutritional Biochemicals Div., International Chemical & Nuclear Corp., Cleveland, Ohio) daily for 2 yr. During the initial period of the studies, when all of the animals had normal renal function, 1,200 mg/day of supplementary P were added to the diet. After completion of the base-line studies, GFR was reduced in all 14 dogs by ligating most of the arterial branches to one kidney and performing a contralateral nephrectomy. Thereafter the animals were divided into three groups. In group I (4 dogs), the 1,200 mg/day P supplement was continued for the entire 2-yr period of study. In group II (4 dogs), the amount of supplementary P was reduced from the initial 1,200 mg/day in proportion to the measured fall in GFR (e.g., with a 50% reduction in GFR, P intake was reduced to 600 mg/day; with a 75% reduction in GFR, intake was reduced to 300 mg/day, etc.). In group III (6 dogs), the same regimen for proportional reduction of P intake was employed as in group II; however, 20 ,g of 25(OH)D3 was administered orally three times per week.
Exogenous creatinine clearance was measured every 2-4 mo, with the dogs fasting, unanesthetized, and standing quietly in slings. The technique employed has been described previously (5) . During the clearance studies, determinations were made of the concentrations of total serum calcium, ionized serum calcium, and serum P (6). In addition, serum P concentrations were measured at weekly intervals throughout the study. Serum immunoreactive PTH levels were measured at 6-mo intervals by the method previously described (25) . 25(OH)D3 serum levels were measured by a protein binding assay as previously described (26) .
Enteric absorption of calcium was estimated as follows: 20-30 ,uCi of 47Ca was given by orogastric tube with 120 mg Ca (as calcium in the diet) to fasting animals, and 100 ml of blood were drawn into heparinized syringes at 2, 4, and 24 h and counted directly in an Armac volume counter (Packard Instruments Co., Inc., Downers Grove, Ill.). The blood was reinfused into each dog immediately after counting. 2 days later, 7-10,Ci 47Ca was administered intravenously in 180 ml of 2.5% dextrose in water by constant infusion at 2.0 ml/ min. The same diet containing 120 mg Ca was given at the start of the infusion. The radioactivity in the blood was measured 4 h, 2 h, and immediately before the start of the intravenous infusion in order to account for the radioactivity remaining from the previously administered oral 47Ca. The variation between these counts was found to be exceedingly small as were the absolute counts. This procedure was discontinued in the later studies and only a single count was performed just before the start of the intravenous infusion. Blood radioactivity was counted at 2, 4, and 24 h after the start of the intravenous infusion. The schedule and calculations are given in Table I .
Rib biopsies were obtained from dogs before the induction of decreased renal mass and then repeated sequentially during the course of the study. The bones were fixed in a 1:3 mixture (vol/vol) of 8% aqueous glutaraldehyde and 100 mM sodium cacodylate. They were then embedded in methylmethacrylate. A series of sections, 5-to 6-gm thick, were obtained with a R-Jung microtome (American Optical Corp., Buffalo, N. Y.). The 1st, 10th, 20th, 30th, 40th, and 50th sections were selected and stained with toluidine blue (pH 2.8). Each following section, 2nd, 11th, 21st, 31st, 41st, and 51st, (20-200 mg) and by using animals with a wide range of GFR (3.5-78 ml/min). The initial and repeat studies in each animal were conducted under identical conditions. The correlation coefficient is 0.93.
each animal under identical conditions; the interval between measurements varied from 2-12 wk. The results comparing the initial with the follow-up measurements are shown in Fig. 1 . The values were closely comparable in most dogs and for the group data. The fractional disappearance of radioactivity from blood was similar in normal dogs and dogs with CRD.
To obtain further information about the effects of CRD on calcium absorption, 47Ca absorption studies were performed on five normal dogs and five dogs that had a decreased renal mass for 3-4 mo before the study. The results are shown in Table II . Calcium absorption in the normal dogs (mean GFR of 66.9+3.6 ml/min) averaged 38.9% at 2 h, 49.2% at 4 h, and 50.7% at 24 h. By contrast, in the dogs with experimental CRD (mean GFR of 8.9+2.8 ml/min), calcium absorption averaged 20.2% at 2 h, 29.1% at 4 h, and 37.6% at 24 h. The differences in the values at 2 and 4 h are statistically significant (P < 0.01 and < 0.02, respectively). Although the mean value for calcium absorption at 24 h was considerably less in the dogs with reduced renal mass than in the normal animals, the (20) and because it was readily available in quantities large enough for the execution of the studies. Fig. 2 were as follows: GFR, 66.2±3.7 ml/min; total calcium, 9.73+0.16 mg/100 ml; ionized calcium, 4.6+0.2 mg/ 100 ml; serum P, 4.1+0.3 mg/ml; PTH, 34.7±43.9 ,ul eq/ml; and 25(OH)D3, 35.9+2.6 ng/ml. After completion of the base-line studies, reduction in renal mass was produced in all the dogs and they were divided into three groups as described in Methods. The reduction of renal mass was similar in all animals, and the level of renal insufficiency was closely comparable in all three groups. Mean values for GFR, measured at 2-to 4-mo intervals over a 2-yr period, Table V . The values for the serum P concentrations measured weekly in each animal in the fasting state throughout the 2-yr period were generally higher than those shown in Table V , averaging 5.35±0.3 mg/100 ml for group I, 4.72±0.1 mg/100 ml for group II, and 4.57±0.1 mg/100 ml in group III. The serum P concentrations obtained during the clearance studies are considered more reliable because they were measured in triplicate and were collected under standardized early morning fasting conditions. Fig. 3 demonstrates the results of PTH assays performed at 6-mo intervals throughout the 2-yr period in each group of dogs. The serum PTH concentrations rose progressively in the animals in group I which were maintained on the 1,200 mg P diet, and at the end of the 2-yr the values were approximately 10 times normal. In the group II animals, which were maintained on a proportionally reduced P intake, the serum immunoreactive PTH concentrations remained normal throughout the 1st yr; then increased, but only to a modest degree, between 12 and 18 mo; but from 18 mo through the end of the study no significant increment occurred. In the group III animals, which were maintained both on proportional reduction of P intake and 25(OH)D3, the immunoreactive PTH concentrations were low or undetectable throughout the study (the lower limit of iPTH detectability is 20 pg/ ml). The serum 25(OH)D3 concentration in this group ranged from 100 to 170 nglml (normal, 22- Ribs from group I dogs exhibited most ofthe morphological changes observed in chronic uremia in man: increased osteoclast count and osteoclastic resorption surface, increased osteoid volume and surface, and a decrease in the mineralization front. Each change became progressively worse with time. The increase in osteoclastic resorption surface paralleled the increase in the concentration of circulating PTH (Figs. 3 and 4) .
When comparisons among the three groups are analyzed, the following changes are observed: (a) the absolute volume of cancellous bone decreased progressively in groups I and II but remained unchanged in group III (Fig. 4) ; (b) there was no change in osteoclast count in any group during the first 6 mo. After 18 mo the count was unchanged in group III, slightly increased in group II, and most increased in group I; (c) the osteoclastic resorption surface was quite different in the three groups: markedly increased in group I, moderately increased in group II, and normal or even decreased in group III. Each of these changes paralleled the changes in circulating PTH concentrations (Fig. 6) ; (d) the osteoid volume was markedly increased in group I, moderately increased in group II, and unchanged in group III (Fig. 5) ; (e) the osteoid surface was markedly increased in groups I and II and unchanged to decreased in group III (Fig. 5) ; (f) the mineralization front was markedly decreased in group I, modestly decreased in group II during the 1st yr and markedly decreased thereafter; it was effectively increased in group III (Fig. 5) .
2 yr after the induction of uremia, one dog from group I and one from group II were treated according to 336 Rutherford et al. normal intake of P (group I) developed severe progressive hyperparathyroidism. When animals with the same degree of renal insufficiency were maintained on a regimen of proportional reduction of P intake (group II), secondary hyperparathyroidism was completely pevented for a full year. The circulating levels of PTH increased modestly between the 12th and through the 18th mo with no further increment thereafter. These observations serve to support the hypothesis that secondary hyperparathyroidism is, at least in part, a consequence of the physiological adaptation which serves to maintain P homeostasis in the face of a progressive reduction in the number of excretory units (7) . 338 Rutherford et al. The effect of hyperparathyroidism on bone morphology appears to be an increase in the osteoclastic resorption surface because the change in osteoclastic resorption surface paralleled changes in the serum concentrations of PTH in all groups (Fig. 6) . Furthermore, the changes were temporally related (cf. Figs.  3 and 4) . The slight increase in osteoclastic resorption surface found in group II at the end of 2 yr also correlates with the failure of proportional reduction of P intake to completely prevent secondary hyperparathyroidism. These data, as well as those from other sources (27) , strongly implies a cause and effect relationship between PTH and osteoclastic resorption surface.
There was general agreement between the osteoclast count and the extent of the osteoclastic resorption surface; however, the increase in resorption surface was observed earlier, suggesting that activity increased before the increase in osteoclast number.
The total bone volume decreased in both groups (I and II) that did not receive 25 The administration of 25(OH)D3 in combination with proportional reduction of P intake prevented the histologic manifestations of renal osteodystrophy. The absolute volume of bone remained normal as did the osteoclast count, the osteoclastic resorption surface, the osteoid surface, and the osteoid volume. The mineralization front actually increased above normal. Hypercalcemia alone has been shown to be incapable of producing an increase in the mineralization front in uremic man (28) . The increase in the mineralization front must, therefore, be ascribed to a more specific mineralization effect of 25(OH)D3 or some more polar metabolite.
These data suggest that the hypercalcemia occurring under the conditions of the study was not primarily a result of continuing net removal of mineral from bone because the absolute volume of bone and the osteoid volume were normal. These data, plus the fact that these animals were hypercalcemic and the circulating levels of immunoreactive PTH were reduced, suggest that the dose of 25(OH)D3 was excessive. The hypercalcemia may have been secondary to excessive calcium absorption. The dose of 25(OH)D3 chosen was based on absorption studies in uremic animals receiving 1,200 mg P/day. Animals with 20% of normal renal function in whom P retention was prevented and in whom the serum P was low might be able to make more 1,25(OH)2D3 than animals on a normal P diet because P has been implicated as an important factor in the regulation of the activity of the 1-hydroxylase system (29) . Therefore, under these conditions, calcium absorption may have been, in fact, greater than normal.
Positive balance and hypercalcemia may have been achieved even if intestinal calcium absorption were normal if renal excretion of calcium were not comparably increased. Maximum rates for calcium excretion/ GFR have not been clearly defined. Brickman et al. (30) noted hypercalcemia in uremic patients after the administration of 1,25(OH)2D3. The same dose given to normal subjects did not produce hypercalcemia even though calcium absorption increased in both groups. The The low serum P concentration (2.64 mg/100 ml) in group III animals may represent selective uptake and sequestering of P in tissue. The tubular reabsorption of P in this group was virtually complete in the studies performed in fasting conditions. This finding could be explained by the known effects of 25(OH)D3 (33) and low concentrations of PTH on tubular P reabsorption (34) . If 25(OH)D3 or a more polar metabolite had any effect on P absorption by the gastrointestinal tract, one would expect it to be enhanced (35) (36) . Thus, the low serum P concentration most likely represents an increase in the uptake of P by bone. Whether the P concentration in other tissue (e.g., muscle) was increased or not is unanswered. This is an important facet which merits further investigation.
These data suggest that in the dog with CRD the obligatory adaptation for renal P excretion plays an important role in the development of secondary hyperparathyroidism and thereby appears to be responsible for the observed increase in the osteoclastic resorption surface. However, the mineralization defect was prevented by the administration of 25(OH)D3.
These studies suggest that in the dog with experimental CRD the development of renal osteodystrophy can be prevented by reduction of P in the diet and the simultaneous administration of 25(OH)D3. It is premature at this time to prognosticate that similar results will be obtained in humans with CRD if the same therapeutic regimen is used. However, based on the pathogenesis of renal osteodystrophy, the results of this study in the dog, and preliminary results in our patients with CRD, a rational approach for the prevention of bone disease in patients with uremia can now be developed.
